deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03639714

A Study of a Personalized Neoantigen Cancer Vaccine

An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Conditions Colorectal Cancer Gastroesophageal Adenocarcinoma Non Small Cell Lung Cancer Urothelial Carcinoma
Interventions GRT-C901 GRT-R902 ipilimumab nivolumab
Updated 19 times since 2018 Last updated: Sep 11, 2023 Started: Feb 13, 2019 Primary completion: Nov 10, 2022 Completion: Nov 10, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Colorectal Cancer and Gastroesophageal Adenocarcinoma and is currently completed. Bristol-Myers Squibb leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Sep 2019 · 5 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Mar 2023 — Oct 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 14 earlier versions

  1. Mar 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Oct 2021 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  5. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  8. Oct 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  14. Sep 2018 — Nov 2018 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Gritstone bio, Inc.
Data source: Gritstone bio, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations